Hookipa's Klaus Orlinger promoted to CSO

23 March 2022

Arenaviral immunotherapies company Hookipa Pharma (Nasdaq: HOOK) has announced that Klaus Orlinger (pictured) has been promoted to the role of chief scientific officer (CSO).

Since joining the Austro-American firm a decade ago, Dr Orlinger has been credited for playing a leading role in driving Hookipa’s arenaviral platform to the clinic and demonstrating the potent antigen-specific T cell response that these novel immunotherapies induce.

Joern Aldag, chief executive of Hookipa, said: “Klaus has been instrumental in advancing our novel arenaviral science into the differentiated, versatile platform technology it is today. He has played a key role in translating scientific theory into candidate immunotherapies in clinical development for infectious disease and cancers, as we have grown as an organization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK